In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Conjugate Dulaglutide (Trulicity) | Synthetic analog Liraglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Conjugate | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 1,919 | 4,766 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 488 (445 in people) | 805 (793 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 124 · 15 active19 more mention it but do not test it | 469 · 30 active49 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Trulicity says: “A GLP-1 analog fused to an IgG4 Fc region, approved for type 2 diabetes and specified cardiovascular risk reduction”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Dulaglutide (Trulicity) | Liraglutide |
|---|---|---|
| Glycemic controlMetabolic and weight | 564537261 | 1,117 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The EMA label for Victoza says: “Adults, adolescents and children 10 years and older with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise”
| Body weightMusculoskeletal | 1781726 | 83481717 |
|---|
| Adverse eventsWhole body | 27823543 | 50449311 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 179179 | 185185 |
|---|
| Heart functionCardiovascular | 171421 | 214198142 |
|---|
| LipidsMetabolic and weight | 37352 | 14313733 |
|---|
| Cardiovascular eventsCardiovascular | 4040 | 13313111 |
|---|
| Kidney functionKidney and urinary | 63567 | 1049932 |
|---|
| Liver fat and liver functionLiver | 20191 | 1361279 |
|---|
| Inflammation markersRespiratory | 6822451 | 117100152 |
|---|
| PharmacokineticsPharmacology | 44404 | 969231 |
|---|
| Blood pressureCardiovascular | 14131 | 1201182 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Dulaglutide (Trulicity) differs from GLP-1 (7-37) at 246 positions.
What is different
Liraglutide differs from GLP-1 (7-37) at 1 position and carries 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 124 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Eli Lilly and Company13,299 participants29 May 2020 to 12 Jun 2025
Type 2 Diabetes Mellitus
Eli Lilly and Company9,901 participants22 Jul 2011 to 21 Aug 2018
Cardiovascular Disease · Diabetes Mellitus, Type 2
Eli Lilly and Company1,842 participants5 Apr 2018 to 10 Oct 2019
Diabetes Mellitus, Type 2
19 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 469 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S9,341 participants31 Aug 2010 to 17 Dec 2015
Diabetes · Diabetes Mellitus, Type 2
GRADE Study Group7,850 participantsMay 2013 to 30 Apr 2021
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Novo Nordisk A/S3,731 participants1 Jun 2011 to 2 Mar 2015
Metabolism and Nutrition Disorder · Obesity
49 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Dulaglutide (Trulicity) | Liraglutide |
|---|---|---|
| Kidney functionKidney and urinaryCompared as: value in the arm that got the peptide, in % | 4% End-stage renal disease · dulaglutide 1.5 mg Dose studied: 1.5 mg weeklyn = 1922018 | 12% Composite kidney disease progression mean follow-up 5.0 yearsn = 5,0472023 |
| Glycemic controlMetabolic and weightCompared as: difference from placebo, in % | −1% HbA1c change difference Dose studied: 1.5 mg once weekly28 weeksn = 2912023 | |
| Body weightMetabolic and weightCompared as: difference from placebo, in kg | −2.9 kg Baseline-adjusted difference in weight change Dose studied: 1.5 mg once weekly12 weeksn = 2552023 | 5.3 kg |
| Patient-reported outcomesWhole bodyCompared as: value in the arm that got the peptide, in points | −1.2 points Treatment satisfaction score change Dose studied: 0.75 mg/week24 weeksn = 632023 | 25.2 points |
| LipidsCardiovascularCompared as: value in the arm that got the peptide, in mmol/l | −0.2 mmol/L Total cholesterol change Placebo: 0.3 mmol/L Dose studied: 1.5 mg weekly26 weeksn not reported2018 | −0.7 mmol/L LDL cholesterol change Placebo: 0.05 mmol/L |
| Gastrointestinal adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 47.4% Gastrointestinal adverse events Placebo: 34.1% Dose studied: 1.5 mg weeklyMedian follow-up 5.4 yearsn = 9,9012019 | 82.7% Gastrointestinal adverse events · liraglutide 3.0 mg |
| Appetite and food intakeMetabolic and weightCompared as: value in the arm that got the peptide, in % | 16.7% Decreased appetite Dose studied: 1.5 mg once weekly12 weeksn = 62022 | 10.9% |
| Adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 82% Adverse events Dose studied: 0.75 mg weekly52 weeksn = 652020 | 89% Adverse events Placebo: 88% |
4%
End-stage renal disease · dulaglutide 1.5 mg
Dose studied: 1.5 mg weeklyn = 1922018
12%
Composite kidney disease progression
mean follow-up 5.0 yearsn = 5,0472023
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Dulaglutide (Trulicity) | Liraglutide |
|---|---|---|
| Cardiovascular eventsCardiovascularCompared as: difference from placebo, in per 1000 person-years | −4.5 per 1000 person-years Absolute reduction · Shown as a change. The study reports a absolute reduction of this size. Dose studied: 1.5 mg weekly5.4 yearsn = 9,9012020 |
−1.09%
HbA1c difference
Dose studied: 1.8 mg once daily26 weeksn = 3442009
Body weight difference
16 weeksn = 972017
Satisfaction score before
24 weeksn not reported2015
Dose studied: 1.8 mg12 weeksn = 142016
Decreased appetite
Dose studied: 1.8 mg26 weeksn = 3682016
−1%
HbA1c change difference
Dose studied: 1.5 mg once weekly28 weeksn = 2912023
−1.09%
HbA1c difference
Dose studied: 1.8 mg once daily26 weeksn = 3442009
−2.9 kg
Baseline-adjusted difference in weight change
Dose studied: 1.5 mg once weekly12 weeksn = 2552023
5.3 kg
Body weight difference
16 weeksn = 972017
−1.2 points
Treatment satisfaction score change
Dose studied: 0.75 mg/week24 weeksn = 632023
25.2 points
Satisfaction score before
24 weeksn not reported2015
−0.2 mmol/L
Total cholesterol change
Placebo: 0.3 mmol/L
Dose studied: 1.5 mg weekly26 weeksn not reported2018
−0.7 mmol/L
LDL cholesterol change
Placebo: 0.05 mmol/L
Dose studied: 1.8 mg12 weeksn = 142016
47.4%
Gastrointestinal adverse events
Placebo: 34.1%
Dose studied: 1.5 mg weeklyMedian follow-up 5.4 yearsn = 9,9012019
82.7%
Gastrointestinal adverse events · liraglutide 3.0 mg
Dose studied: 3.0 mg once daily68 weeksn = 1272022
16.7%
Decreased appetite
Dose studied: 1.5 mg once weekly12 weeksn = 62022
10.9%
Decreased appetite
Dose studied: 1.8 mg26 weeksn = 3682016
82%
Adverse events
Dose studied: 0.75 mg weekly52 weeksn = 652020
89%
Adverse events
Placebo: 88%
Dose studied: 3.0 mg or maximum tolerated dose once daily56 weeksn = 822025
No comparable result 74 randomized-trial results measure it in another way or another unit. |
| Treatment adherence and retentionPharmacologyCompared as: value in the arm that got the peptide, in % | No comparable result 2 randomized-trial results measure it in another way or another unit. | 65% Trial completion Placebo: 53.4% Dose studied: 3.0 mg/d56 weeksn = 1322025 |
|---|
| Body compositionMetabolic and weightCompared as: difference from placebo, in % | No comparable result 2 randomized-trial results measure it in another way or another unit. | −0.24% Treatment difference Dose studied: 3.0 mg target dose, once daily40 weeksn = 1282024 |
|---|
| Inflammation markersImmune and inflammationCompared as: difference from placebo, in ng/ml | No comparable result 6 randomized-trial results measure it in another way or another unit. | 14.9 ng/ml Serum NGAL difference Dose studied: 3 mg/d52 weeksn = 1272025 |
|---|
−4.5 per 1000 person-years
Absolute reduction · Shown as a change. The study reports a absolute reduction of this size.
Dose studied: 1.5 mg weekly5.4 yearsn = 9,9012020
No comparable result
74 randomized-trial results measure it in another way or another unit.
No comparable result
2 randomized-trial results measure it in another way or another unit.
65%
Trial completion
Placebo: 53.4%
Dose studied: 3.0 mg/d56 weeksn = 1322025
No comparable result
2 randomized-trial results measure it in another way or another unit.
−0.24%
Treatment difference
Dose studied: 3.0 mg target dose, once daily40 weeksn = 1282024
No comparable result
6 randomized-trial results measure it in another way or another unit.
14.9 ng/ml
Serum NGAL difference
Dose studied: 3 mg/d52 weeksn = 1272025